BridgeBio's FDA decision on infigratinib, a treatment for achondroplasia
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Pro members see it live.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Pro members see it live.
What the company said
“Oral infigratinib for achondroplasia has a February 4, 2027 PDUFA date, with Priority Review.”
More on BBIO and the FDA calendar
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Use this page
How to cite
Breakaway, BridgeBio's FDA decision on infigratinib, a treatment for achondroplasia, Nov 16, 2026, getbreakaway.com/biotech/BBIO-infigratinib
Journalists: email support@getbreakaway.com for the data behind this page.